Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Image: CNBC
Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
"The new product and the diversification of geography is what has led to such a strong Q3," Moderna CEO Stéphane Bancel said in an interview ahead of the results.
For example, he said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025. Bancel noted that Covid is a seasonal business and vaccine contracts are typically established in the first quarter, so Moderna's shot only had a "small launch" to start with last year.
This page shows only an excerpt. The full story is published by CNBC.
More news View More
:strip_icc():format(webp)/kly-media-production/medias/7438729/original/060986300_1780214817-Konferensi_pers_pembentukan_Danantara_Sumberdaya_Indonesia.jpg)
:strip_icc():format(webp)/kly-media-production/medias/9392023/original/010077500_1793965740-email-attachment_2026_11_06_pramita-tristiawati_menko-ahy-pembangunan-underpass-bitung-sudah-707-persen-awal-tahun-bisa-digunakan_IMG-20261106-WA0016__1_.jpg)
:strip_icc():format(webp)/kly-media-production/medias/9391911/original/084642000_1793955916-WhatsApp_Image_2026-11-06_at_15.10.06.jpeg)
:strip_icc():format(webp)/kly-media-production/medias/9391270/original/092147800_1793881832-IMG_0593.jpg)
:strip_icc():format(webp)/kly-media-production/medias/9391952/original/053873600_1793958680-WhatsApp_Image_2026-11-06_at_15.10.07__1_.jpeg)
